Cellular Biomedicine Group (NASDAQ:CBMG) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Cellular Biomedicine Group (NASDAQ:CBMG) from a hold rating to a buy rating in a research report report published on Thursday morning, ValuEngine reports.

Other equities research analysts have also recently issued research reports about the company. BidaskClub upgraded Cellular Biomedicine Group from a sell rating to a hold rating in a research note on Friday, July 19th. Cantor Fitzgerald initiated coverage on Cellular Biomedicine Group in a research note on Tuesday, June 25th. They set an overweight rating and a $27.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $27.50.

NASDAQ CBMG traded down $0.43 during trading on Thursday, hitting $13.51. The stock had a trading volume of 12,226 shares, compared to its average volume of 27,785. The firm has a market cap of $259.80 million, a P/E ratio of -6.62 and a beta of 2.71. The company has a 50-day moving average price of $14.55. Cellular Biomedicine Group has a 12 month low of $12.04 and a 12 month high of $25.00.

Cellular Biomedicine Group (NASDAQ:CBMG) last released its earnings results on Tuesday, April 30th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. The firm had revenue of $0.05 million for the quarter. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%. On average, equities research analysts predict that Cellular Biomedicine Group will post -2.08 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Cellular Biomedicine Group by 3.8% during the 4th quarter. BlackRock Inc. now owns 657,998 shares of the biotechnology company’s stock worth $11,620,000 after purchasing an additional 23,992 shares in the last quarter. Nikko Asset Management Americas Inc. raised its stake in shares of Cellular Biomedicine Group by 37.0% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 532,318 shares of the biotechnology company’s stock worth $8,799,000 after purchasing an additional 143,798 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Cellular Biomedicine Group by 38.0% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 528,418 shares of the biotechnology company’s stock worth $8,735,000 after purchasing an additional 145,616 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of Cellular Biomedicine Group by 10.0% during the 2nd quarter. ARK Investment Management LLC now owns 314,378 shares of the biotechnology company’s stock worth $5,197,000 after purchasing an additional 28,616 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Cellular Biomedicine Group by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 126,067 shares of the biotechnology company’s stock worth $2,226,000 after purchasing an additional 14,621 shares in the last quarter. Institutional investors own 17.87% of the company’s stock.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.

Further Reading: How a Put Option Works

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.